These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7794332)

  • 1. p53 and bladder cancer.
    Li WW; Li VW; Tsakayannis D
    N Engl J Med; 1995 Apr; 332(14):957; author reply 958. PubMed ID: 7794332
    [No Abstract]   [Full Text] [Related]  

  • 2. p53 and bladder cancer.
    Xing X
    N Engl J Med; 1995 Apr; 332(14):957-8. PubMed ID: 7877657
    [No Abstract]   [Full Text] [Related]  

  • 3. p53 and bladder cancer.
    Wood LL
    N Engl J Med; 1995 Apr; 332(14):958. PubMed ID: 7877658
    [No Abstract]   [Full Text] [Related]  

  • 4. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts.
    Aprikian AG; Sarkis AS; Reuter VE; Cordon-Cardo C; Sheinfeld J
    Semin Urol; 1993 Aug; 11(3):137-44. PubMed ID: 8210835
    [No Abstract]   [Full Text] [Related]  

  • 6. Accumulation of nuclear p53 and tumor progression in bladder cancer.
    Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
    N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.
    Furihata M; Inoue K; Ohtsuki Y; Hashimoto H; Terao N; Fujita Y
    Cancer Res; 1993 Oct; 53(20):4823-7. PubMed ID: 8402668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
    Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
    BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.
    Swana HS; Grossman D; Anthony JN; Weiss RM; Altieri DC
    N Engl J Med; 1999 Aug; 341(6):452-3. PubMed ID: 10438269
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
    Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
    Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
    Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
    Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivariate analysis DNA/cytokeratin 7 and flow cytometric measurement of MIB-1 in superficial transitional carcinoma of the bladder (TCC). Methodological aspects and prognostic implications.
    Leonardi E; Cristofori A; Reich A; Dalla Palma P
    Eur J Histochem; 1997; 41 Suppl 2():133-4. PubMed ID: 9859817
    [No Abstract]   [Full Text] [Related]  

  • 15. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
    Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
    Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor markers and prognostic parameters in urinary bladder cancer].
    Schneider AW; Huland H
    Urologe A; 1990 Mar; 29(2):71-6. PubMed ID: 2184571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunohistochemical study of p53 and Ki-67 antigen expression in bladder carcinoma].
    Yuge F; Hirakata H; Igarashi H; Kodama M; Kawata N; Takimoto Y
    Hinyokika Kiyo; 1999 Jul; 45(7):453-6. PubMed ID: 10466059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluations of protein p53 overexpression in cancer of the bladder: prognostic value].
    Popov Z; Hoznek A; Colombel M; Bastuji S; Abbou CC; Chopin DK
    Chirurgie; 1996; 121(6):461-9. PubMed ID: 8978142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FISH: a tool we really need?
    Pycha A
    Eur Urol; 2007 Sep; 52(3):630-2; discussion 633-5. PubMed ID: 17416454
    [No Abstract]   [Full Text] [Related]  

  • 20. [The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer].
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakácsova M; Zámefnik L; Dvorácek J
    Cas Lek Cesk; 2007; 146(1):63-7. PubMed ID: 17310587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.